Our findings indicate that TARC and MDC are actively involved in the pathogenesis of AD and their expression, opposite to that of eotaxin, is strongly associated with clinical picture of atopic dermatitis.

Non-melanoma skin cancers (NMSCs) are the most common malignancies diagnosed in Caucasian populations. Basal cell carcinoma (BCC) is the most frequent skin cancer, followed by squamous cell carcinoma (SCC). Unfortunately, most European cancer registries do not record individual types of NMSC. To evaluate the incidence of primary BCCs and SCCs regarding age, sex, tumour site and tumour subtype to determine trends in epidemiology of both cancers. Retrospective analysis of BCCs and SCCs diagnosed and treated across seven sites in Poland from 1999 to 2019. We recorded 13,913 NMSCs occurring in 10,083 patients. BCC represented 85.2% of all cases. SCC patients were older than BCC patients (77.1 ± 11.3 years vs. 70.1 ± 12.3 years, p < 0.01). The nodular subtype was the most common subtype of BCC, followed by the superficial and infiltrative subtypes. The superficial BCC subtype was more common on photoprotected areas (p < 0.01), whereas the nodular BCC subtype occurred on the face (p < 0.01). The high-risk SCC subtypes were more common on face compared to low-risk SCC subtypes (p < 0.01). BCC and SCC are common malignancies developing at various ages and anatomical sites. These data underline the need for better registration policies regarding NMSC in order to improve prevention and treatment strategies for these tumours.

Podstawą klinicznej diagnostyki różnicowej czerniaków skóry i kwalifikacji do biopsji wycinającej jest obecnie dermoskopia. Dla ustalenia rozpoznania i określenia najważniejszych czynników rokowniczych podstawowe znaczenie ma biopsja wycinająca podejrzanych w kierunku wczesnego czerniaka zmian barwnikowych skóry (wycięcie całej grubości skóry i powierzchownej warstwy tkanki tłuszczowej). Wczesne rozpoznanie i chirurgiczne usunięcie czerniaka nie tylko poprawia rokowanie, ale daje szansę wyleczenia około 90% chorych. Kolejne etapy postępowania terapeutycznego obejmują kwalifikację chorych do radykalnego wycięcia blizny po biopsji wycinającej z właściwy-mi marginesami oraz wykonania biopsji węzła wartowniczego. W przypadku przerzutów do regionalnych węzłów chłonnych postępowaniem z wyboru jest wykonanie radykalnej limfadenektomii. Zaleca się włączanie chorych na czerniaki skóry o wysokim ryzyku nawrotu (przerzuty do węzłów chłonnych i/lub owrzodzenie pierwotnej zmiany) do prospektywnych badań klinicznych nad leczeniem uzupełniającym. Obecność przerzutów odległych wiąże się ze złym rokowaniem. W sytuacji uogólnienia nowotworu konieczne jest wykonanie badania w kierunku mutacji genu BRAF. Długoletnie przeżycia dotyczą głównie chorych poddanych resekcji pojedynczych ognisk przerzutowych. W systemowym leczeniu -przede wszystkim pierwszej linii -u chorych z obecnością mutacji BRAF V600 znajduje zastosowanie inhibitor BRAF -wemurafenib lub dabrafenib (preferencyjnie w skojarzeniu z inhibitorem MEK) oraz -niezależnie od statusu mutacji BRAF -immunoterapia przeciwciałami anty-PD-1 (niwolumab lub pembrolizumab), ewentualnie ipilimumab (przeciwciało anty-CTLA4). Recommendations for diagnosis and therapy of cutaneous melanomaDermoscopy is currently the standard method for clinical differential diagnosis of cutaneous melanoma and for qualifying a lesion for excision biopsy. Full thickness excision biopsy of suspicious melanomatous skin lesions is likely to be diagnosed as early melanomaand is crucial in establishing diagnosis and defining prognostic factors. Early diagnosis and surgical removal of cutaneous melanoma not only improves prognosis, but it is also associated with approximately 90% likelihood of cure. Next steps in the therapeutic management of cutaneous melanoma following

The pathophysiology of acne vulgaris depends on active sebaceous glands, implying that selective destruction of sebaceous glands could be an effective treatment. We hypothesized that light-absorbing microparticles could be delivered into sebaceous glands, enabling local injury by optical pulses. A suspension of topically applied gold-coated silica microparticles exhibiting plasmon resonance with strong absorption at 800 nm was delivered into human pre-auricular and swine sebaceous glands in vivo, using mechanical vibration. After exposure to 10–50 J cm−2, 30 milliseconds, 800 nm diode laser pulses, microscopy revealed preferential thermal injury to sebaceous follicles and glands, consistent with predictions from a computational model. Inflammation was mild; gold particles were not retained in swine skin 1 month after treatment, and uptake in other organs was negligible. Two independent prospective randomized controlled clinical trials were performed for treatment of moderate-to-severe facial acne, using unblinded and blinded assessments of disease severity. Each trial showed clinically and statistically significant improvement of inflammatory acne following three treatments given 1–2 weeks apart. In Trial 2, inflammatory lesions were significantly reduced at 12 weeks (P=0.015) and 16 weeks (P=0.04) compared with sham treatments. Optical microparticles enable selective photothermolysis of sebaceous glands. This appears to be a well-tolerated, effective treatment for acne vulgaris.

No abstract

There exists a disconnect between the European psoriasis treatment guidelines and the various CEE country-specific biologic coverage eligibilities. The cost of biologic therapy for psoriasis is not solely and directly responsible for the different use rates amongst the CEE countries. Psoriasis may not be perceived by all payers as a serious disease that can be successfully treated in a cost-effective manner.

Psoriasis is a chronic inflammatory disease affecting approximately 1-3% of the general population. Although skin lesions are the primary clinical manifestation of the condition, psoriasis-especially moderate to severe-is currently regarded as a systemic disease, not only associated with the development of psoriatic arthritis but also linked to a range of other health consequences including cardiovascular complications. In view of new data on the pathogenesis of psoriasis, very rapid progress in the development of new therapeutic approaches, and in particular the registration of new drugs, a need arose to update the guidelines for the diagnosis and treatment of this nosological entity. The aim of the recommendations of the Polish Dermatological Society is to outline the most recent literature and formulate guidelines for the treatment of psoriasis that may be useful in daily dermatological practice. However, the final decision regarding the diagnostic and therapeutic procedure should always be made individually for each patient based on the patient's current clinical status and the most up-to-date scientific reports. STReSZCZeNie Łuszczyca jest przewlekłą chorobą zapalną dotyczącą około 1-3% populacji ogólnej. Choć zmiany skórne stanowią podstawową manifesta

Psoriasis is a chronic inflammatory skin disease affecting approximately 1-3% of the general population. Recent years have brought a considerable progress in the treatment of this dermatosis, particularly with respect to patients with moderate to severe psoriasis. A growing range of increasingly available systemic therapies poses new challenges to physicians providing care to patients with psoriasis. On account of the fact that new antipsoriatic drugs have become available on the pharmaceutical market since the publication of previous guidelines for the treatment of psoriasis, an update has become necessary. The first part of the guidelines refers to mild psoriasis and selected special forms of this disease. The aim of the recommendations of the Polish Dermatological Society is to summarize the most recent literature reports and formulate guidelines that may be potentially useful for dermatologists-venereologists in their daily clinical practice. However, the final decision regarding the diagnostic and therapeutic procedure should always be made individually for each patient based on the patient's current clinical status and the most up-to-date literature reports.